Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer
- 23 Downloads
Ten year disease-free survival (DFS) results of the Naples randomized trial of adjuvant tamoxifen (TM), 30 mg per day for 2 years versus no therapy according to receptor levels, are reported. From Feb. 1, 1978, through Dec. 31, 1983, 308 pre- and postmenopausal patients with early breast cancer entered the trial. Estrogen receptor (ER) data were available on 239 (77.6%) patients, progesterone receptor (PgR) data on 194 (63.0%), and both receptor data on 181 (58.8%).
ER and PgR were assayed by dextran-coated charcoal technique in a single laboratory. The effect of adjuvant TM was significantly related to ER and PgR concentration of the primary tumor. The greatest TM benefit on DFS was evident in patients with the highest levels of receptors. The interaction between the treatment effect and receptor concentration was found whether ER and PgR were considered separately or together.
Key wordsadjuvant therapy breast cancer endocrine therapy estrogen receptor progesterone receptor tamoxifen
Unable to display preview. Download preview PDF.
- 2.Byar DP, Sears ME, McGuire WL: Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Europ J Cancer 15: 299–310, 1979Google Scholar
- 6.Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 57: 608–611, 1988Google Scholar
- 7.Rutqvist LE, Cedermark B, Glas U, Johansson H, Nordenskjold B, Skoog L, Somell A, Theve T, Friberg S, Askergren J: The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 10: 255–266, 1987PubMedGoogle Scholar
- 8.Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, Rasmussen BB: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet i: 16–19, 1985Google Scholar
- 9.Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh: Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet ii: 171–175, 1987Google Scholar
- 10.Bianco AR, De Placido S, Gallo C, Pagliarulo C, Marinelli A, Petrella G, D'Istria M, Delrio G: Adjuvant therapy with tamoxifen in operable breast cancer. Lancet ii: 1095–1099, 1988Google Scholar
- 11.Early Breast Cancer Trialists' Cooperative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28896 women. N Engl J Med 319: 1681–1692, 1988Google Scholar
- 13.Pichon MF, Milgrom E: Characterization and assay of progesterone receptor in human mammary carcinoma. Cancer Res 37: 464–471, 1977Google Scholar
- 14.Kaplan EL, Meier P: Nonparametric estimation from in complete observation. J Am Stat Assoc 53: 457–481, 1958Google Scholar
- 15.Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep 50: 163–170, 1966Google Scholar
- 16.Cox DR: Regression models and life tables. J R Stat Soc (B) 34: 187–220, 1972Google Scholar
- 18.Bonomi P, Gale M, Von Roenn J, Anderson K, Johnson P, Wolter J, Economou S: Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen. Semin Oncol 15, suppl. 1: 26–33, 1988Google Scholar
- 20.Horwitz KB: The central role of progesterone receptors and progestational agents in the management and treatment of breast cancer. Semin Oncol 15. suppl. 1: 14–19, 1988Google Scholar
- 21.King WJ, De Sombre ER, Jensen EV, Greene GL: Com parison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors. Cancer Res 45: 293–304, 1985Google Scholar